SunRISe-1 Data: Promising Complete Response Rate, Durable Outcomes With TAR-200 for NMIBC

Sia Daneshmand, MD, discusses the groundbreaking findings from the SunRISe-1 study, highlighting TAR-200’s impressive complete response rates as a monotherapy for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. Dr. Daneshmand describes how TAR-200’s sustained drug delivery sets it apart from conventional intravesical therapies, offering a promising new approach to bladder-sparing strategies. He delves into the study’s safety, tolerability, and durable responses, as well as its potential to supplement or delay the need for radical cystectomy in eligible patients.